
|Videos|February 9, 2016
Dr. Michael Lim on Toxicities of Checkpoint Inhibitors in Glioblastoma
Author(s)Michael Lim, MD
Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses checkpoint inhibitors in glioblastoma.
Advertisement
Michael Lim, MD, director of Brain Tumor Immunotherapy, associate professor of Neurosurgery, Johns Hopkins Medicine, discusses checkpoint inhibitors in glioblastoma. Lim says medical professionals should be aware of the toxicities that come along with these checkpoint inhibitors, as well as be able to recognize the first signs of toxicities.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5







































